Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents

Bibliography

• Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat Rep 2007;55:1-119
   PubMedGoogle Scholar
• Mathers CD, Lopez AD, Murray CJL. The burden of disease and mortality by condition: data, methods, and results for 2001. In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors, Global burden of disease and risk factors. The World Bank and Oxford University Press, Washington, D.C. and New York City, NY; 2006. p. 45-240
   Google Scholar
• Schocken DD, Benjamin EJ, Fonarow GC, Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008;117:2544-65
   PubMed Web of Science ®Google Scholar
• Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54
   PubMed Web of Science ®Google Scholar
• Rauchhaus M, Doehner W, Francis DP, Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7
   PubMed Web of Science ®Google Scholar
• Anker SD, Chua TP, Ponikowski P, Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34
   PubMed Web of Science ®Google Scholar
• Okonko DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail 2004;10(1 Suppl):S5-9
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Friday G, Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Larson MG, Leip EP, Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106:3068-72
   PubMed Web of Science ®Google Scholar
• Vasan RS, Wilson PWF. Epidemiology and causes of heart failure. In: Rose BD, editor, UpToDate. UpToDate, Waltham, MA; 2007
   Google Scholar
• Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93(9):1137-46
   PubMed Web of Science ®Google Scholar
• McCullough PA, Philbin EF, Spertus JA, Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002;39:60-9
   PubMed Web of Science ®Google Scholar
• Stewart S. Beyond the numbers: the individual challenges of combating consistently poor survival in heart failure. Am Heart J 2008;155:195-6
   PubMed Web of Science ®Google Scholar
• Ho KK, Anderson KM, Kannel WB, Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15
   PubMed Web of Science ®Google Scholar
• Rodeheffer RJ, Jacobsen SJ, Gersh BJ, The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 1993;68:1143-50
   PubMed Web of Science ®Google Scholar
• MacIntyre K, Capewell S, Stewart S, Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000;102:1126-31
   PubMed Web of Science ®Google Scholar
• Colucci WS. Prognosis of heart failure. In: Rose BD, editor, UpToDate. UpToDate, Waltham, MA; 2007
   Google Scholar
• Gwadry-Sridhar FH, Flintoft V, Lee DS, A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med 2004;164:2315-20
   PubMed Web of Science ®Google Scholar
• Wolinsky FD, Overhage JM, Stump TE, The risk of hospitalization for congestive heart failure among older adults. Med Care 1997;35:1031-43
   PubMed Web of Science ®Google Scholar
• Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-12
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM, Heart Disease and Stroke Statistics–2010 Update. A Report From the American Heart Association. Circulation 2010;121:e46-e215
   PubMed Web of Science ®Google Scholar
• Cleland JG. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 1998;19(Suppl P):P32-9
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med Econ 1993;6:91-8
   Google Scholar
• Lee WC, Chavez YE, Baker T, Luce BR. Economic burden of heart failure: a summary of recent literature. Heart Lung 2004;33:362-71
   PubMed Web of Science ®Google Scholar
• Berry C, Murdoch DR, McMurray JJ. Economics of heart failure. Eur J Heart Fail 2001;3:283-91
   PubMed Web of Science ®Google Scholar
• Tang WH, Miller H, Partin M, Anemia in ambulatory patients with chronic heart failure: a single-center clinical experience derived from electronic medical records. J Am Coll Cardiol 2003;41(Suppl A):S1061-75
   Google Scholar
• Schrier SL. Approach to the adult patient with anemia. In: Rose BD, editor, UpToDate. UpToDate, Waltham, MA; 2007
   Google Scholar
• Anand IS, Chandrashekhar Y, Ferrari R, Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 1993;70:357-62
   PubMedGoogle Scholar
• Silverberg DS, Wexler D, Blum M, The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-44
   PubMed Web of Science ®Google Scholar
• Tanner H, Moschovitis G, Kuster GM, The prevalence of anemia in chronic heart failure. Int J Cardiol 2002;86:115-21
   PubMed Web of Science ®Google Scholar
• Cromie N, Lee C, Struthers AD. Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart 2002;87:377-8
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107(2):223-5
   PubMed Web of Science ®Google Scholar
• Anand I, McMurray JJ, Whitmore J, Anemia is more common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003;107:223-5
   PubMed Web of Science ®Google Scholar
• Horwich TB, Fonarow GC, Hamilton MA, Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-6
   PubMed Web of Science ®Google Scholar
• Witte KK, Desilva R, Chattopadhyay S, Are hematinic deficiencies the cause of anemia in chronic heart failure? J Am Coll Cardiol 2004;147:924-30
   Web of Science ®Google Scholar
• Kalra PR, Bolger AP, Francis DP, Effect of anemia on exercise tolerance in chronic heart failure in men. Am Heart J 2004;147:924-30
   PubMed Web of Science ®Google Scholar
• Felker GM, Gattis WA, Leimberger JD, Usefulness of anemias as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003;92:625-8
   PubMed Web of Science ®Google Scholar
• Herzog CA, Muster HA, Li S, Collins AJ. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail 2004;10:467-72
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Blum M, Iaina A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduces hospitalization. Clin Nephrol 2003;60(Suppl 1):S93-102
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Iaina A, Anemia, chronic renal disease and congestive heart failure – the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006;38:295-310
   PubMed Web of Science ®Google Scholar
• Akram K, Pearlman BL, Parker M, Akram I. Congestive hear failure-related anemia and a role for erythropoietin. Int J Cardiol 2007;117:296-305
   PubMed Web of Science ®Google Scholar
• van der Meer P, Lipsic E, Westenbrink BD, Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005;112:1743-7
   PubMed Web of Science ®Google Scholar
• Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454-61
   PubMed Web of Science ®Google Scholar
• Guglin ME, Koul D. Cardiovascular effects of erythropoietin. Anemia and beyond. Cardiol Rev 2006;14(4):200-4
   PubMedGoogle Scholar
• Bergmann MW, Fliser D. Eryhthropietin und Herzinsuffizienz. Der Kardiologe 2007;1:43-9
   Google Scholar
• Brines M, Grasso G, Fiordaliso F, Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2003;101:14907-12
   Web of Science ®Google Scholar
• Fiordaliso F, Chimenti S, Staszewsky L, A nonerythropoietic derivative of eryhtropoietin protects the myocardium frosch ischemia- reperfusion injufry. Proc Natl Acad Sci USA 2008;102:2046-51
   Web of Science ®Google Scholar
• Macdougall IC, Gray SC, Elston O, Pharmakokinetics of a novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Am Soc Nephrol 1999;10:2392-5
   PubMed Web of Science ®Google Scholar
• Stoian I, Manolescu B, Atanasiu V, Lupescu O. New alternatives for erythropoietin therapy in chronic renal failure. Cent Eur J Med 2007;2:361-78
   Web of Science ®Google Scholar
• van der Meer P, Groenveld HF, Januzzi JL Jr, van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009;95:1309-14
   PubMed Web of Science ®Google Scholar
• Geisler BP, van Dam RM, Gazelle GS, Goehler A. Risk of bias in meta-analysis on erythropoietin-stimulating agents in heart failure. Heart 2009;95:1278-9; author reply 9
   PubMed Web of Science ®Google Scholar
• The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Intervention. 2008 February 2008 [cited 2008 4-20]; 5.0.2: Available from: http://www.cochrane-handbook.org
   Google Scholar
• Komajda M. Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. J Card Fail 2004;10(1 Suppl):S1-4
   PubMed Web of Science ®Google Scholar
• Felker GM, Shaw LK, Stough WG, O'Connor CM. Anemia in patients with heart failure and preserved systolic function. Am Heart J 2006;151:457-62
   PubMed Web of Science ®Google Scholar
• Feldman L, Wang Y, Rhim JS, Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 2006;66:135-45
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rube C, Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, Erythropoietin or darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009;(3):CD007303
   Google Scholar
• Acs G, Acs P, Beckwith SM, Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5
   PubMed Web of Science ®Google Scholar
• Yasuda Y, Fujita Y, Matsuo T, Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-9
   PubMed Web of Science ®Google Scholar
• Brower V. FDA finalizes REMS program for ESAs; Amgen continues to study risks. J Natl Cancer Inst 2010;102:592-3
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
   PubMed Web of Science ®Google Scholar
• Parfrey PS, Foley RN, Wittreich BH, Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16:2180-9
   PubMed Web of Science ®Google Scholar
• Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 2000;11:335-42
   PubMed Web of Science ®Google Scholar
• Furuland H, Linde T, Ahlmen J, A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-61
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Inrig JK, Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-8
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Sapp S, A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2010;77:239-46
   PubMed Web of Science ®Google Scholar
• Allen LA, Anstrom KJ, Horton JR, Relationship between anemia and health care costs in heart failure. J Card Fail 2009;15:843-9
   PubMedGoogle Scholar
• Adams KF, Jr., Pina IL, Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. Am Heart J 2009;158:965-71
   PubMed Web of Science ®Google Scholar
• Go AS, Yang J, Ackerson LM, Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006;113:2713-23
   PubMed Web of Science ®Google Scholar
• Groenveld HF, Januzzi JL, Damman K, Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-27
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24
   PubMed Web of Science ®Google Scholar
• Bohlius J, Langensiepen S, Schwarzer G, Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98
   PubMed Web of Science ®Google Scholar
• Fauci AS, Braunwald E, Kasper DL, Harrison's principles of internal medicine. 17th edition. McGraw-Hill Medical, New York: 2008
   Google Scholar
• Lichtman MA, Williams WJ. Williams hematology. 7th edition. McGraw-Hill, Medical Pub Division, New York: 2006
   Google Scholar
• Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107:1747-50
   PubMed Web of Science ®Google Scholar
• Lambert JR, Duliege AM, Stead R, Pharmacokinteics (PK), safety, and pharmacodynamics (PD) of Hematide, a synthetic peptide-based erythropoiesis stimulating agent (ESA), in a Phase 1 single dose, dose escalating study in normal healthy volunteers (NHVS). American Society for Clinical Pharmacology and Therapeutics 2006 Annual Meeting; Baltimore, MD; 2006. p. 19 Abstract PI-46. Available from: http://www.ascpt.org/annualmeeting2007/meetingabstracts06.pdf [Last accessed 9 June 2010]
   Google Scholar
• Aranesp. Scientific Discussion, London UK, European Medicines Agencies; 2008. Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/aranesp/129901en6.pdf [Last accessed 9 June 2010]
   Google Scholar
• Macdougall IC, Robson R, Opatrna S, Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-5
   PubMed Web of Science ®Google Scholar
• Cramer P, Martinet J. Erythropoietin. France Biotech, Paris, France; 2005
   Google Scholar
• Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002;69:265-74
   PubMed Web of Science ®Google Scholar